Skip to main content
Explore URMC

menu

Dupilumab Study

Research Question:
Does dupilumab affect the immune system, water loss in the skin, and the amount of bacteria in the skin of adults with atopic dermatitis (eczema)?

Basic Study Information

Purpose:
Our researchers are studying a new medication called dupilumab to determine how it affects the immune system, water loss in the skin, and the amount of bacteria in the skin of adults with atopic dermatitis (eczema).The Food and Drug Administration recently approved dupilumab for the treatment of moderate-to-severe atopic dermatitis. You will be randomized (like flipping a coin) with a 66% chance of receiving dupilumab and 33% chance of receiving placebo for 6 weeks. After 6 weeks everyone will receive 10 weeks of dupilumab. Your skin will be checked for bacteria and barrier function and your immune system will be monitored.

Study Reference #: 68402

Lead Researcher (Principal Investigator)

Lead Researcher: Lisa Beck

Study Contact Information

Study Coordinator: Jean Sauvain
Phone: (585) 275-0374
Email: Jean_sauvain@URMC.Rochester.edu

Additional Study Details

Parking:  Free
Transportation Coverage:  No
Reimbursement:  Yes

Contact This Study

This field is required
This field is required
You must agree to be contacted to continue.

Return to Search